Product Images Tadalafil

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 10 images provide visual information about the product associated with Tadalafil NDC 68071-3758 by Nucare Pharmaceuticals, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

pdp - 68071 3758 7

pdp - 68071 3758 7

This text contains information about NuCare Pharmaceuticals, including their product with lot number 00000 and expiry date 00-00. It also provides details about Tadalafil 10mg tablets with different lot numbers and serial numbers. It includes a warning to keep the product out of reach of children and store it at a controlled temperature of 68-77°F. The text mentions contacting a doctor for medical advice on side effects and reporting any side effects to the FDA.*

f35596a7-figure-01 - f35596a7 figure 01

f35596a7-figure-01 - f35596a7 figure 01

f35596a7-figure-02 - f35596a7 figure 02

f35596a7-figure-02 - f35596a7 figure 02

This is not a readable text.*

f35596a7-figure-03 - f35596a7 figure 03

f35596a7-figure-03 - f35596a7 figure 03

This is a chart showing the standing systolic blood pressure (BP) measured in millimeters of mercury (mmHg) in relation to time. The text also mentions the administration of Tadalafil 20 mg and doxazosin 8 mg.*

f35596a7-figure-04 - f35596a7 figure 04

f35596a7-figure-04 - f35596a7 figure 04

This text appears to contain information related to a study or experiment involving the administration of different medications and their effects on systolic blood pressure at various time points. The study involves the use of tadalafil, doxazosin, and placebos at different dosages and timings. The data presented seems to show the impact of these medications on systolic blood pressure.*

f35596a7-figure-05 - f35596a7 figure 05

f35596a7-figure-05 - f35596a7 figure 05

f35596a7-figure-06 - f35596a7 figure 06

f35596a7-figure-06 - f35596a7 figure 06

This text provides information about the change in IPSS Total Score over the course of treatment with Tadalafil tablets 5 mg compared to a placebo. The data shown indicates a statistically significant difference between the two treatment groups (p<0.001). The graph shows the duration of treatment in weeks on the x-axis, with the change from baseline score on the y-axis.*

f35596a7-figure-07 - f35596a7 figure 07

f35596a7-figure-07 - f35596a7 figure 07

This text is not readable.*

f35596a7-figure-08 - f35596a7 figure 08

f35596a7-figure-08 - f35596a7 figure 08

LS Mean Change from Baseline for TadalafilFinasteride and PlaceboFinasteride groups is represented. The Least Squares Treatment Difference between the two groups can be analyzed.*

f35596a7-figure-09 - f35596a7 figure 09

f35596a7-figure-09 - f35596a7 figure 09

This text appears to be a reference to a clinical trial involving Tadalafil tablets. It provides information on the dosage of 5 mg and mentions the comparison with a placebo. Additionally, there is a statistical significance indicated by '*p<0.01'. The graph below shows the duration of treatment in weeks.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.